Melanotan I
Melanotan I is a synthetic analogue of alpha-melanocyte-stimulating hormone (alpha-MSH) that acts primarily at the melanocortin-1 receptor (MC1R). Its pharmaceutical form, afamelanotide (brand name Scenesse), is a controlled-release subcutaneous implant that has received regulatory approval in some regions, including the EU and the United States, for use in adults with the rare genetic condition erythropoietic protoporphyria (EPP). That approval is narrow: it covers a specific implant product, a specific indication, and clinician administration. Gray-market material sold as "Melanotan 1" for tanning or other purposes is a separate, unapproved research chemical and should not be conflated with the approved implant.
Side effects & risks
Reported and studied adverse effects of melanocortin agonists in this class include nausea, facial flushing, headache, and fatigue, most commonly noted early in exposure. Generalized darkening of the skin and, importantly, darkening or change in existing moles and freckles is a recognized effect and a key safety concern. Because these compounds can alter melanocytic lesions, monitoring of moles and skin lesions is emphasized, and any new, changing, or asymmetric lesion warrants prompt dermatological evaluation. Injection-site or implant-site reactions have been reported with the relevant delivery routes. Gray-market injectable material carries additional risks including unknown purity, contamination, and dosing errors that are absent from the approved, clinician-administered implant. This compound is not appropriate for people with a personal or family history of melanoma or significant atypical nevi without specialist input, and anyone with numerous or atypical moles should exercise particular caution. Use of any material in this class should involve a clinician and, given the pigmentary effects, baseline and ongoing dermatology review.
Latest studies
Acute impact of afamelanotide on UVR erythemal and melanogenic responses in healthy humans in vivo: an exploratory study.
Nine healthy adults were given a graded series of UVB doses on one buttock, then received a 16 mg afamelanotide implant — the licensed form of the peptide often called melanotan-1 — and six days later had the same UVB series applied to the other side. Sunburn redness across the dose range fell measurably after the implant, and instrument-measured melanin density rose by roughly 2 to 3 percent. Notably, melanin staining in skin biopsies did not change, so the redness reduction is not obviously explained by pigment alone. The authors read this as early in-human support for an anti-inflammatory action seen previously in cell studies.
Afamelanotide improves quality of life and light tolerance in Austrian erythropoietic protoporphyria patients.
A real-world study of 20 Austrian patients found that afamelanotide (melanotan-1) was associated with markedly longer pain-free sun exposure, better quality of life, and fewer phototoxic reactions in erythropoietic protoporphyria.
Insights into Tanning Biology and Tanning Products.
A systematic review of self-tanning agents reports that unregulated melanotan use has been associated with serious adverse effects including rhabdomyolysis, renal infarction, and priapism.
Community discussion
Community-reported · not verified
These are synthesised observations from public forum discussions. They are community-reported, not clinically verified, and should not inform any health decision. The peptide does not cure, treat, or prevent any condition based on these reports.
“8 weeks on reta + mots c + a little mt1 😎”
An eight-week personal log of a combined regimen of retatrutide, MOTS-c, and a small amount of melanotan-1, shared as a progress report on a multi-compound stack popular in body-recomposition circles.
Reported protocols (with caveats)
In its approved form, afamelanotide is a subcutaneous implant inserted by a healthcare professional, typically dosed at intervals of several weeks during periods of higher light exposure, strictly within the EPP indication and clinical supervision. This is the only administration route with regulatory approval and should be directed by a clinician. Separately, gray-market "Melanotan 1" is reported in community and research-use-only contexts as a reconstituted subcutaneous injection, with reported protocols describing a short daily loading phase followed by less frequent maintenance dosing. These reported figures come from user reports and non-clinical sources, not controlled trials, and vary widely. Such gray-market use is research use only and is not recommended; no self-administered protocol here should be read as guidance.